Our news journalists obtained a quote from the research from Optum, "Potential denosumab 60 mg off-label use was observed based on claims, but many had evidence of on-label indications based on ...
In the extension, all subjects, regardless of original randomization, received open-label Prolia (60 mg) every six months. The long-term group received up to 10 years of Prolia (three years in the ...
FDA’s boxed warning on denosumab follows study results showing increased and early risks of severe hypocalcemia in patients on dialysis. The Food and Drug Administration (FDA) has added a new boxed ...
THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...
THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a ...
MONTREAL -- A combination regimen of high-dose teriparatide (Forteo) and denosumab (Prolia) increased hip and spine bone mineral density (BMD) to a greater extent than standard combination therapy ...
On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and XGEVA® (denosumab) in the European Economic Area. AVT03 is approved ...
Amgen has announced the presentation of data at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting highlighting its expertise in bone biology research and commitment to ...
(RTTNews) - Alvotech (ALVO) announced that the European Commission has approved AVT03, a biosimilar to Amgen's Prolia and Xgeva for use across Europe. Prolia is indicated to treat osteoporosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results